Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.
Neuren Pharmaceuticals Limited has announced that Vanguard Group, Inc. and its controlled entities have ceased to be a substantial holder in the company as of February 28, 2025. This change in shareholding could impact the company’s market perception and investor confidence, as Vanguard Group was a significant stakeholder with notable voting power.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and other neurological conditions. The company is known for its innovative approach to addressing unmet medical needs in the global healthcare market.
YTD Price Performance: 9.15%
Average Trading Volume: 647
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1B
For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.